Last reviewed · How we verify
Tunlametinib plus Vemurafenib
This combination blocks BRAF and MEK signaling in the MAPK pathway to inhibit growth of BRAF-mutant melanoma and other cancers.
This combination blocks BRAF and MEK signaling in the MAPK pathway to inhibit growth of BRAF-mutant melanoma and other cancers. Used for BRAF V600E-mutant melanoma, BRAF V600E-mutant non-small cell lung cancer, BRAF V600E-mutant colorectal cancer.
At a glance
| Generic name | Tunlametinib plus Vemurafenib |
|---|---|
| Sponsor | Shanghai Kechow Pharma, Inc. |
| Drug class | BRAF inhibitor + MEK inhibitor combination |
| Target | BRAF V600E and MEK1/2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Vemurafenib is a BRAF V600E inhibitor that directly targets mutated BRAF kinase, while trametinib (tunlametinib) is a MEK1/2 inhibitor that blocks downstream signaling. Together, they provide dual inhibition of the MAPK pathway to overcome resistance and improve efficacy in BRAF-mutant tumors.
Approved indications
- BRAF V600E-mutant melanoma
- BRAF V600E-mutant non-small cell lung cancer
- BRAF V600E-mutant colorectal cancer
Common side effects
- Rash
- Diarrhea
- Nausea
- Fatigue
- Arthralgia
- Pyrexia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tunlametinib plus Vemurafenib CI brief — competitive landscape report
- Tunlametinib plus Vemurafenib updates RSS · CI watch RSS
- Shanghai Kechow Pharma, Inc. portfolio CI